The Future of Clinical Trials: “Synthetic Patients” Powered by Artificial Intelligence
In a recent video, Professor Pablo Foncillas discusses the future of clinical trials and how they may enter a new era with the use of “synthetic patients” powered by artificial intelligence (AI).
Foncillas explains, “Generative AI is about to give a facelift to the clinical trial sector. No more real humans for the control group. In their place, there will be virtual humans, created by an algorithm that has analyzed medical records from a diverse patient population.”
The integration of AI into clinical trials could have significant implications. “It could unlock a new world in the pharmaceutical sector, where drugs would be approved faster and where trial costs would be reduced,” said Lloyd Minor, dean of the Stanford School of Medicine. Additionally, AI’s ability to discover new antibiotics in record time is a potential game-changer.
However, there are still challenges that AI may not easily resolve, such as long waiting periods and the low availability of health system professionals.
The impact of AI on healthcare remains a topic of interest. Will the future be better with AI? These questions are explored in the video, “Why aren’t humans needed to test new medicines?” featuring Pablo Foncillas.